Clinical Trial

Towards Cure Via Only Ultra-short ICB in CSCC

Name: Towards Cure Via Only Ultra-short ICB in CSCC — clinical trial record (NCT06823479)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MATISSE 2

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to determine whether cutaneous squamous cell carcinoma patients can be cured using only immunotherapy, without surgery or radiotherapy.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-02-06.

Status change: Not Yet Recruiting → Recruiting 2025-05-22

Trial Details

NCT Number	NCT06823479
Lead Sponsor	The Netherlands Cancer Institute Collaborators: UMC Utrecht, Erasmus Medical Center, Maastricht University Medical Center, Amsterdam UMC, location VUmc
Conditions	Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Cutaneous Squamous Cell Carcinoma
Enrollment	41 participants
Start Date	2025-05-14
Primary Completion	2029-02 (estimated)
Study Completion	2029-02 (estimated)
Updated on ClinicalTrials.gov	2025-05-29